Advertisement
ALLO vs FDMT
Which Stock Would AI Choose? Allogene Therapeutics (ALLO) vs. 4D Molecular Therapeutics (FDMT) Stock Comparison
Key Takeaways
- ALLO (Allogene Therapeutics) is a clinical-stage developer of "off-the-shelf" allogeneic CAR T cell therapies for blood cancers and autoimmune diseases, while FDMT (4D Molecular Therapeutics) focuses on gene therapies for retinal disease and cystic fibrosis.
- Both companies are pre-revenue biotechnology firms whose valuations hinge on late-stage clinical trial catalysts, making them sensitive to data readouts and financing conditions.
- FDMT carries a stronger sell-side profile, with a "Strong Buy" consensus and an average price target well above its recent trading range, while ALLO holds a more mixed "Hold"-leaning analyst stance.
- Both stocks have been volatile in recent weeks, trading below near-term moving averages amid a broader pullback in speculative biotech names.
- Investors can track additional coverage, news, and intraday moves for these tickers on dedicated pages: ALLO Major News, ALLO Today's Price Move, FDMT Major News, and FDMT Today's Price Move.
- For automated, data-driven market analysis across these and thousands of other tickers, explore Trending AI Robots.
Introduction
This stock comparison examines two clinical-stage biotechnology companies operating in distinct but equally high-stakes corners of modern medicine. ALLO, Allogene Therapeutics, is developing off-the-shelf (allogeneic) CAR T cell therapies for cancer and autoimmune conditions, while FDMT, 4D Molecular Therapeutics, is advancing gene therapies targeting the eye and lungs. Because neither firm yet generates meaningful product revenue, their relative performance is driven by clinical data, regulatory milestones, cash runway, and market sentiment rather than earnings. This comparison is most relevant to growth-oriented and biotech-focused investors who evaluate pre-commercial drug developers on pipeline quality, capital efficiency, and near-term catalysts.
ALLO Overview and Recent Performance
Allogene Therapeutics (ALLO) is a clinical-stage immuno-oncology company developing "off-the-shelf" allogeneic CAR T cell therapies — treatments engineered from healthy-donor cells rather than a patient's own cells, which could shorten manufacturing timelines and broaden access. Its lead candidate, cema-cel, is being evaluated in the pivotal Phase II ALPHA3 study as a first-line consolidation therapy for large B-cell lymphoma (LBCL).
In recent weeks, the company reported narrower-than-expected quarterly losses, supported by lower research and development (R&D) spending, and maintained full-year operating expense guidance. Management has emphasized an interim futility analysis showing substantially higher measurable residual disease (MRD) negativity among treated patients, alongside an outpatient treatment profile. A recent public offering extended the company's cash runway into 2029, easing near-term dilution concerns. Despite these developments, ALLO shares have pulled back in recent market activity, trading below their 20-day moving average after a strong earlier run, and the stock carries notably elevated short interest relative to its float.
FDMT Overview and Recent Performance
4D Molecular Therapeutics (FDMT) is a clinical-stage genetic medicines company whose lead candidate, 4D-150, is a gene therapy designed to provide long-lasting suppression of vascular endothelial growth factor (VEGF, a protein that drives abnormal blood-vessel growth) in the eye. It is being studied for wet age-related macular degeneration (AMD) and diabetic macular edema (DME), with a Phase III trial underway. The company is also developing 4D-710 for cystic fibrosis.
Recent market activity has reflected a mix of analyst enthusiasm and caution. Several firms have reiterated Buy ratings with price targets well above the stock's trading level, while others have maintained Hold ratings. A strategic partnership with Otsuka provided an upfront payment and extended the company's cash runway, supporting late-stage development. However, FDMT shares have also experienced volatility in recent weeks, with notable insider selling reported during the period. The company continues to guide toward Phase III data readouts expected later in the decade.
Trending AI Robots
Tickeron operates hundreds of AI Trading Bots that collectively trade thousands of different tickers, spanning varied strategies, timeframes, and risk profiles. Because not every bot is equally suited to every market environment, Tickeron curates a dedicated Trending AI Robots section highlighting the strategies currently demonstrating the most relevant performance characteristics. These bots differ in trading style, holding period, performance history, and the specific set of tickers they trade, allowing users to match an automated approach to their own objectives. For traders comparing names like ALLO and FDMT, reviewing the current selection can offer a data-driven complement to fundamental research. Explore Trending AI Robots to see which strategies are resonating in today's market.
Head-to-Head Comparison
These two companies differ sharply in therapeutic focus and risk profile. ALLO targets oncology and autoimmune disease with a platform that could scale more efficiently than traditional CAR T therapies, but its value rests heavily on the ALPHA3 trial and the durability of allogeneic cells. FDMT pursues one-time gene therapies in ophthalmology, where a single injection could replace chronic, recurring anti-VEGF treatments — an attractive proposition but one dependent on long-term durability and safety data.
On growth drivers, ALLO is nearing nearer-term interim readouts and benefits from an extended cash runway, though its elevated short interest signals meaningful skepticism. FDMT enjoys a more supportive analyst consensus and partnership-backed funding, yet faces a longer wait for pivotal data and competition in the crowded wet AMD space. In terms of market sentiment, FDMT currently commands higher institutional conviction on a ratings basis, while ALLO presents a more contested, higher-conviction contrarian setup.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely lean toward FDMT in the current environment. Its combination of a "Strong Buy" analyst consensus, partnership-secured financing, and a well-defined late-stage catalyst set points to relatively greater stability and institutional backing. ALLO, while offering potentially earlier catalysts and a differentiated platform, currently displays weaker near-term trend consistency, elevated short interest, and a more mixed analyst stance. This assessment is probabilistic rather than definitive, and either stock could re-rate quickly on clinical news. Relative positioning and catalyst timing, not absolute quality, drive the current differentiation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a Hold and FDMT is a Buy.
ALLO in -15.09% downward trend, sliding for three consecutive days on November 11, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ALLO declined for three days, in 283 of 312 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALLO as a result. In 73 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for ALLO turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 41 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
The Aroon Indicator for ALLO entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALLO advanced for three days, in 185 of 228 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
ALLO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.824) is normal, around the industry mean (3.498). P/E Ratio (-1.576) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (91.743) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. ALLO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALLO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
FDMT sees its Stochastic Oscillator climbs out of oversold territory
On October 28, 2026, the Stochastic Oscillator for FDMT moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 57 instances where the indicator left the oversold zone. In 48 of the 57 cases the stock moved higher in the following days. This puts the odds of a move higher at over 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where FDMT's RSI Oscillator exited the oversold zone, 22 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on FDMT as a result. In 72 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for FDMT just turned positive on October 29, 2026. Looking at past instances where FDMT's MACD turned positive, the stock continued to rise in 39 of 47 cases over the following month. The odds of a continued upward trend are 83%.
Following a +10.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where FDMT advanced for three days, in 217 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
FDMT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day moving average for FDMT crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FDMT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for FDMT entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.660) is normal, around the industry mean (3.498). P/E Ratio (-4.658) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (9.662) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. FDMT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FDMT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ALLO | FDMT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 16 | 19 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 48 Fair valued | 25 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 97 | |
PRICE GROWTH RATING 1..100 | 88 | 46 | |
P/E GROWTH RATING 1..100 | 12 | 59 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
FDMT's Valuation (25) in the null industry is in the same range as ALLO (48) in the Biotechnology industry. This means that FDMT’s stock grew similarly to ALLO’s over the last 12 months.
FDMT's Profit vs Risk Rating (100) in the null industry is in the same range as ALLO (100) in the Biotechnology industry. This means that FDMT’s stock grew similarly to ALLO’s over the last 12 months.
FDMT's SMR Rating (97) in the null industry is in the same range as ALLO (97) in the Biotechnology industry. This means that FDMT’s stock grew similarly to ALLO’s over the last 12 months.
FDMT's Price Growth Rating (46) in the null industry is somewhat better than the same rating for ALLO (88) in the Biotechnology industry. This means that FDMT’s stock grew somewhat faster than ALLO’s over the last 12 months.
ALLO's P/E Growth Rating (12) in the Biotechnology industry is somewhat better than the same rating for FDMT (59) in the null industry. This means that ALLO’s stock grew somewhat faster than FDMT’s over the last 12 months.
| ALLO | FDMT | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 86% | 2 days ago 79% |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 84% |
| Momentum ODDS (%) | 2 days ago 88% | 2 days ago 81% |
| MACD ODDS (%) | 2 days ago 87% | 2 days ago 83% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 87% |
| Advances ODDS (%) | 9 days ago 81% | 4 days ago 83% |
| Declines ODDS (%) | 2 days ago 90% | 11 days ago 84% |
| BollingerBands ODDS (%) | 2 days ago 82% | 2 days ago 78% |
| Aroon ODDS (%) | 2 days ago 89% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALLO’s FA Score shows that 1 FA rating(s) are green while FDMT’s FA Score has 1 green FA rating(s).
- ALLO’s FA Score: 1 green, 4 red.
- FDMT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALLO’s TA Score shows that 4 TA indicator(s) are bullish while FDMT’s TA Score has 6 bullish TA indicator(s).
- ALLO’s TA Score: 4 bullish, 4 bearish.
- FDMT’s TA Score: 6 bullish, 3 bearish.
Price Growth
ALLO (@Biotechnology) experienced а -24.36% price change this week, while FDMT (@Biotechnology) price change was +5.78% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +11.66%. For the same industry, the average monthly price growth was +1.65%, and the average quarterly price growth was -13.40%.
Reported Earning Dates
ALLO is expected to report earnings on Mar 18, 2027.
FDMT is expected to report earnings on Feb 26, 2027.
Industries' Descriptions
@Biotechnology (+11.66% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ALLO and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALLO has been loosely correlated with EDIT. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLO jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To ALLO | 1D Price Change % | ||
|---|---|---|---|---|
| ALLO | 100% | -3.41% | ||
| EDIT - ALLO | 49% Loosely correlated | -4.99% | ||
| AXON - ALLO | 44% Loosely correlated | +4.26% | ||
| RCKT - ALLO | 43% Loosely correlated | +1.22% | ||
| ARRY - ALLO | 43% Loosely correlated | +9.94% | ||
| FDMT - ALLO | 43% Loosely correlated | +4.25% | ||
More | ||||